I think the market is saying show me, not trial data but trial funding. In B-OM's case, the market wants to see how IPIX is going to fund Phase 3. I'm very confident that Leo will find a partner for B-OM. When that happens, IPIX's MC will correct itself as a Phase 3 biotech.